Annual report pursuant to Section 13 and 15(d)

Revenue - AstraZeneca AB (Details)

v3.8.0.1
Revenue - AstraZeneca AB (Details) - USD ($)
$ in Thousands
 12 Months Ended
May 02, 2017
Dec. 31, 2017
Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]      
Milestone payments   $ 12,573 $ 1,655
Non-current deferred revenue   46,542 $ 1,409
AstraZeneca      
Deferred Revenue Arrangement [Line Items]      
Research collaboration agreement term 5 years    
Milestone payments   12,600  
AstraZeneca | Upfront Payment      
Deferred Revenue Arrangement [Line Items]      
Allocable arrangement consideration $ 45,000    
AstraZeneca | Upfront Payment | Estimated Development and Manufacturing Services      
Deferred Revenue Arrangement [Line Items]      
Allocable arrangement consideration 8,200    
AstraZeneca | Upfront Payment | Relative Selling Price Method      
Deferred Revenue Arrangement [Line Items]      
Allocable arrangement consideration $ 53,200    
AstraZeneca | License and Collaboration Agreement      
Deferred Revenue Arrangement [Line Items]      
Period after effective date agreements may be terminated 12 months    
Contract termination advance notice period 90 days    
Agreement termination advance notice period if marketing approval obtained 180 days    
Agreement termination notice period upon material breach by the Company 180 days    
Agreement termination notice period upon breach of payment obligations by the Company 30 days    
Contract termination due to material breach, additional notice period if the breach is not susceptible 180 days    
AstraZeneca | Substantive Development and Sales Milestone | Minimum      
Deferred Revenue Arrangement [Line Items]      
Milestone payments $ 72,200    
AstraZeneca | Substantive Development and Sales Milestone | Maximum      
Deferred Revenue Arrangement [Line Items]      
Milestone payments 611,400    
AstraZeneca | Non-Substantive Development and Sales Milestones | Minimum      
Deferred Revenue Arrangement [Line Items]      
Milestone payments 366,200    
AstraZeneca | Non-Substantive Development and Sales Milestones | Maximum      
Deferred Revenue Arrangement [Line Items]      
Milestone payments 1,100,000    
AstraZeneca | Sales Milestones | Maximum      
Deferred Revenue Arrangement [Line Items]      
Milestone payments $ 1,000,000    
Deferred revenue   28,600  
Non-current deferred revenue   $ 16,300